key: cord-1013496-ekfd0dn7 authors: Karim, Marwah; Saul, Sirle; Ghita, Luca; Sahoo, Malaya Kumar; Ye, Chengjin; Bhalla, Nishank; Jin, Jing; Park, Jun-Gyu; Martinez-Gualda, Belén; East, Michael Patrick; Johnson, Gary L.; Pinsky, Benjamin A.; Martinez-Sobrido, Luis; Asquith, Christopher R. M.; Narayanan, Aarthi; De Jonghe, Steven; Einav, Shirit title: Numb-associated kinases are required for SARS-CoV-2 infection and are cellular targets for therapy date: 2022-03-20 journal: bioRxiv DOI: 10.1101/2022.03.18.484178 sha: cf086f6eb66a95c709f041f907c1ee080646beb9 doc_id: 1013496 cord_uid: ekfd0dn7 The coronavirus disease 2019 (COVID-19) pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to pose serious threats to global health. We previously reported that AAK1, BIKE and GAK, members of the Numb-associated kinase family, control intracellular trafficking of multiple RNA viruses during viral entry and assembly/egress. Here, using both genetic and pharmacological approaches, we probe the functional relevance of NAKs for SARS-CoV-2 infection. siRNA-mediated depletion of AAK1, BIKE, GAK, and STK16, the fourth member of the NAK family, suppressed SARS-CoV-2 infection in human lung epithelial cells. Both known and novel small molecules with potent AAK1/BIKE, GAK or STK16 activity suppressed SARS-CoV-2 infection. Moreover, combination treatment with the approved anti-cancer drugs, sunitinib and erlotinib, with potent anti-AAK1/BIKE and GAK activity, respectively, demonstrated synergistic effect against SARS-CoV-2 infection in vitro. Time-of-addition experiments revealed that pharmacological inhibition of AAK1 and BIKE suppressed viral entry as well as late stages of the SARS-CoV-2 life cycle. Lastly, suppression of NAKs expression by siRNAs inhibited entry of both wild type and SARS-CoV-2 pseudovirus. These findings provide insight into the roles of NAKs in SARS-CoV-2 infection and establish a proof-of-principle that pharmacological inhibition of NAKs can be potentially used as a host-targeted approach to treat SARS-CoV-2 with potential implications to other coronaviruses. Briefly, HEK293 cells were transiently transfected with the NanoLuc ® Fusion DNA and 239 incubated at 37°C. 20 hours post-transfection, NanoBRET ™ tracer reagent and RMC-242 were 240 added to the cells and incubated at 37°C for 2 hours. Nanoluciferase-based bioluminescence 241 resonance energy transfer (BRET) was measured using NanoBRET™ Nano-Glo ® Substrate on a 242 GloMax ® Discover Multimode Microplate Reader (Promega). 243 244 2.14. In vitro kinase assays. In vitro kinase assays to determine IC 50 of gefitinib for AAK1 and 245 BIKE were performed by the LabChip platform (Nanosyn). 246 profiling was performed as previously described (Duncan et al., 2012; Asquith et al., 2018) . 249 Briefly, SUM159 cell lysates were incubated with DMSO or the indicated concentration of 250 RMC-76 or DMSO for 30 min on ice. Kinases fragments were then detected and analyzed by 251 mass spectrometry. Kinase abundance was quantified label-free using MaxQuant software. 252 253 2.16. Data analysis of combination drug treatment. The MacSynergy II program was used to 254 perform synergy/antagonism analysis, as previously described (Prichard and Shipman, 1996; 255 Neveu et al., 2015; Bekerman et al., 2017) . The combination's effect is determined by subtracting 256 the theoretical additive values from the experimental values. A synergy peak is depicted by the 257 three-dimensional differential surface plot above a theoretical additive plane and antagonism as 258 depressions below it (Prichard and Shipman, 1990) . Matrix data sets in 3 replicates were 259 assessed at the 95% confidence level for each experiment. Synergy and log volume were 260 calculated. 261 262 2.17. Statistical Analysis. All data were analyzed with GraphPad Prism software. Half-maximal 263 effective concentrations (EC 50 ) and half-maximal cytotoxic concentrations (CC 50 ) were 264 measured by fitting of data to a 3-parameter logistic curve. P values were calculated by ordinary 265 1-way ANOVA with Dunnett's multiple comparisons tests as specified in each figure legend. 266 267 3. Results 268 To probe the functional relevance of NAKs to WT SARS-CoV-2 infection, we first used an 270 RNAi approach. Calu-3 (human lung epithelial) cells were depleted of AAK1, BIKE, GAK and 271 STK16 individually via siRNAs (Figure 1A) , and knock-down efficiency was confirmed via 272 RT-qPCR ( Figure 1B) . NAKs depletion had no apparent effect on Calu-3 cell viability, as 273 measured by an alamarBlue assay ( Figure 1B) . Nevertheless, it reduced SARS-CoV-2 infection 274 by 89%±1.1% (siAAK1), 91%±5.7% (siBIKE), 91%±5.0% (siGAK), and 96%±4.3% To determine whether a similar effect on SARS-CoV-2 infection to that achieved genetically can 286 be achieved pharmacologically, we determined the anti-SARS-CoV-2 activity of a set of 5 287 compounds: (5Z)-7-oxozeanol, sunitinib, erlotinib, gefitinib and baricitinib (Table 1 and Figure 288 vitro 346 Next, we determined whether chemically distinct, novel small molecules with anti-NAK activity 347 (Table 1 and Grant U24DK116204). S.E. is a Chan Zuckerberg Biohub investigator was supported by a Postdoctoral Fellowship in Translational Medicine by the PhRMA 779 We thank the Stanford in vitro BSL3 service Center and its Director Dr Garhyan for assistance in the BSL3. We also thank the staff of Stanford Clinical Virology 781 Laboratory for their help sequencing the SARS-CoV-2 USA-WA1/2020 isolate used in this wrote the first version of the manuscript Small-molecule antiviral β -d-N 4-hydroxycytidine inhibits a 807 proofreading-intact coronavirus with a high genetic barrier to resistance SGC-GAK-1: a chemical probe for cyclin G associated kinase 810 (GAK) Identification and optimization of 4 anilinoquinolines as inhibitors 812 of cyclin G associated kinase Design and Analysis of the 4 Anilinoquin (az) oline Kinase 814 Inhibition Profiles of GAK/SLK/STK10 Using Quantitative Structure Activity Relationships Design of a cyclin G associated kinase (GAK)/epidermal growth 817 factor receptor (EGFR) inhibitor set to interrogate the relationship of EGFR and GAK in 818 chordoma SARS-CoV-2 infects cells after viral entry via clathrin-mediated 820 endocytosis Anticancer kinase inhibitors impair intracellular viral trafficking and 822 exert broad-spectrum antiviral effects Neuropilin-1 facilitates SARS-CoV-2 cell entry and 824 infectivity Generation and Characterization of recombinant SARS-CoV-2 826 expressing reporter genes Generation of Recombinant SARS CoV 2 Using a Bacterial Artificial 828 Chromosome Identification of an adaptor-associated kinase, AAK1, as a 830 regulator of clathrin-mediated endocytosis Bioluminescence Profiling of NanoKAZ/NanoLuc Luciferase Using a 832 Chemical Library of Coelenterazine Analogues Gram-scale synthesis of luciferins derived from coelenterazine and 834 original insights into their bioluminescence properties Comprehensive analysis of kinase inhibitor selectivity Dynamic reprogramming of the kinome in response to targeted MEK 838 inhibition in triple-negative breast cancer SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is 840 Blocked by a Clinically Proven Protease Inhibitor Optimization of 4-Anilinoquinolines as Dengue Virus Inhibitors. 842 Molecules Serine/threonine kinase 16 and MAL2 regulate constitutive secretion of 844 soluble cargo in hepatic cells Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized 846 Patients Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19 Cloning and characterization of a novel protein kinase that impairs 850 osteoblast differentiation in vitro Thiol drugs decrease SARS-CoV-2 lung injury in vivo and disrupt 852 SARS-CoV-2 spike complex binding to ACE2 in vitro The target landscape of clinical kinase drugs SARS-CoV-2 structure and replication characterized by in situ cryo-856 electron tomography TMPRSS2 expression dictates the entry route used by SARS CoV 2 to 858 infect host cells. The EMBO journal Identification and selected reaction monitoring (SRM) quantification 860 of endocytosis factors associated with Numb Discovery of a Highly Selective STK16 Kinase Inhibitor A serine/threonine kinase 16-based phospho-proteomics screen 864 identifies WD repeat protein-1 as a regulator of constitutive secretion COVID-19: breaking down a global health crisis. Ann Clin Microbiol 867 Antimicrob Efficacy and safety of baricitinib for the treatment of hospitalised 869 adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-870 controlled phase 3 trial Discovery of 3-phenyl-and 3-N-piperidinyl-isothiazolo[4,3-b] 872 pyridines as highly potent inhibitors of cyclin G-associated kinase Identification and targeting of an interaction between a tyrosine motif 875 within hepatitis C virus core protein and AP2M1 essential for viral assembly AP-2-associated protein kinase 1 and cyclin G-associated kinase regulate 878 hepatitis C virus entry and are potential drug targets A resorcylic acid lactone, 5Z-7-oxozeaenol, prevents 880 inflammation by inhibiting the catalytic activity of TAK1 MAPK kinase kinase An oral SARS-CoV-2 M(pro) inhibitor clinical candidate for the 883 treatment of COVID-19 A three-dimensional model to analyze drug-drug 885 interactions Analysis of combinations of antiviral drugs and design of 887 effective multidrug therapies BIKE regulates dengue virus infection and is a cellular target for broad-889 spectrum antivirals Feasibility and biological rationale of repurposing sunitinib and erlotinib 891 for dengue treatment Systematic analysis of SARS-CoV-2 infection of an ACE2-893 negative human airway cell Baricitinib as potential treatment for 2019-nCoV acute respiratory 895 disease GAK, a regulator of clathrin mediated membrane trafficking, localizes not 897 only in the cytoplasm but also in the nucleus Identification and evaluation of 4-anilinoquin(az)olines as potent inhibitors 899 of both dengue virus (DENV) and Venezuelan equine encephalitis virus (VEEV) Discovery of pan-ErbB inhibitors protecting from SARS-CoV-2 902 replication, inflammation, and lung injury by a drug repurposing screen Potent antiviral activity of novel multi-substituted 4-anilinoquin(az)olines AAK1 regulates Numb function at an early step in 907 clathrin mediated endocytosis Family-wide Structural Analysis of Human Numb-Associated Protein 909 COVID-19: combining antiviral and anti-inflammatory treatments. 911 Lancet Infect Dis JAK inhibition reduces SARS-CoV-2 liver infectivity and modulates 913 inflammatory responses to reduce morbidity and mortality Distinct genetic determinants and mechanisms of SARS-CoV-2 915 resistance to remdesivir Synthesis and Structure-Activity Relationships of 3,5-Disubstituted-917 pyrrolo[2,3-b]pyridines as Inhibitors of Adaptor-Associated Kinase 1 with Antiviral Activity Multiplex SARS-CoV-2 Genotyping Reverse Transcriptase PCR for 920 Population-Level Variant Screening and Epidemiologic Surveillance Sunitinib reduces the infection of SARS-CoV CoV-2 partially by inhibiting AP2M1 phosphorylation Mechanism and in vitro pharmacology of TAK1 inhibition by (5Z) Interactions between the Hepatitis C Virus Nonstructural 2 Protein and 928 Host Adaptor Proteins 1 and 4 Orchestrate Virus Release Rescue of SARS-CoV-2 from a Single Bacterial Artificial Chromosome Multiple roles for cyclin G-associated kinase in clathrin-mediated 932 sorting events Genome-scale RNAi screen for host factors required for HIV replication A pneumonia outbreak associated with a new coronavirus of probable bat 936 origin STK-16-1N-1 295 nM RIPK2 (110 nM), ADCK3 (190 nM), NLK (520 nM)